Nivolumab and relatlimab with lab-made memory NK cells
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 1 study tests a new form of immune cells (NK cells) along with nivolumab and relatlimab for advanced melanoma that has worsened after prior PD-1/PD-L1 treatments. It may help your body recognize and attack melanoma cells more strongly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic melanoma confirmed by biopsy, and it got worse after at least 12 weeks or 2 doses of PD-1/PD-L1 treatment (like nivolumab or pembrolizumab).
- You are 18 or older, and you must be well enough for treatment (ECOG 0–2).
- Your heart, liver, kidneys, and lungs must meet study lab/health cutoffs (including oxygen level on room air and heart pumping strength).
- You must be able to stop immune-suppressing medicines like steroid medications for a set time before cell collection and around the infusion (small “low-dose” steroids may be allowed if medically needed).
- If you have had melanoma in the brain that caused symptoms, it must be treated and stable for at least 4 weeks, and you must be off anti-seizure medicine and steroids for 7 days before starting the study drug treatment phase.
- You must not be pregnant or breastfeeding, and you must use two reliable birth-control methods during the study and for months after the last relatlimab dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two immunotherapy drugs (nivolumab and relatlimab) for people with advanced melanoma that cannot be removed by surgery or has spread. These drugs help your immune system fight the cancer more effectively.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.